Workhorse rose more than 4% before the market opened and announced its participation in the 2024 Advanced Clean Transportation Expo.

Related posts

• Joyson Electronics: Net profit after deducting non-attributed profits in the first quarter was 311 million yuan, a year-on-year increase of 134.18%

  Securities Times e Company News, on April 25, Joyson Electronics announced its first quarter results for 2024. The company achieved operating income of 13.3 billion yuan, and net profit after non-attributable to the parent company increased by 134.18% year-on-year to 311 million yuan. Net profit attributable to the parent company increased by 134.18% year-on-year. Increased 53.11% to 307 million yuan; overall gross profit margin continued to optimize, increasing 2.5 percentage points year-on-year to 15.5%; new full life cycle orders were 29.8 billion yuan, with new energy vehicle-related orders accounting for approximately 77%, and performance continued to maintain strong momentum.

  US stock market April 25, 2024

• Zydus Lifesciences and MSN partner for US generic Cabozantinib supply

  Zydus Lifesciences Ltd.’s shares were up by 2.25 per cent to ₹1,031.95 on the BSE. The company announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE, entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets, a generic version of CABOMETYX, intended for the US market.

  US stock market May 17, 2024

• Xpeng Motors fell more than 4% before results

  Gelonghui, May 21 | Chinese auto stocks and U.S. stocks fell collectively before the market opened. Among them, Xpeng Motors fell more than 4% to US$7.94.

  US stock market May 21, 2024

• Nordisk fell 1.1% in premarket as the U.S. Senate launches investigation into Novo Nordisk\’s GLP-1 drug pricing

  Gelonghui, April 25 | Nord Nordisk (NVO.US) U.S. stocks fell 1.1% before the market opened, to US$124.74. On the news, U.S. Senate Health, Education, Labor and Pensions Committee Chairman Bernie Sanders said on Wednesday that the committee is launching an investigation into Novo Nordisk\’s pricing. In a letter sent to Novo Nordisk\’s CEO on Wednesday, Sanders asked Novo Nordisk to provide \”internal communications about the U.S. pricing of the drug\” and explain why Ozempic and Wegovy have the same ingredient (semaglutide). ), Wegovy’s pricing is obviously more expensive. Sanders stressed that the price of GLP-1 drugs \”must come down\” so that consumers can afford them and the government doesn\’t go bankrupt by reimbursing them.

  US stock market April 25, 2024

• Broker’s call: Cipla (Buy)

  Target: ₹1,552

  US stock market May 14, 2024

• JPMorgan Chase CEO warns: U.S. inflation may last longer and the market is too optimistic about a soft landing

  JPMorgan CEO Jamie Dimon said in an interview at the JPMorgan Global Markets Conference on Thursday that the market is underestimating how long inflation is likely to last because a series of factors are keeping prices rising.

  US stock market May 17, 2024